Top Markets
Coin of the day
Diagnocure, Inc. Diagnocure, Inc.

Diagnocure, Inc.

DGCRF
Κατάταξη σε μετοχές #41417
Diagnocure, Inc. is a Canadian life sciences company dedicated to developing... Diagnocure, Inc. is a Canadian life sciences company dedicated to developing and commercializing innovative products for cancer diagnosis. Its core business revolves around advanced molecular diagnostic tests designed for the identification and management of cancerous conditions. The company's portfolio includes the PCA3 test for prostate cancer diagnosis, as well as the Guanylyl Cyclase C (GCC) marker and the Previstage GCC colorectal cancer staging test, both vital for patients with colorectal cancer. They also offer PCP, a multi-marker diagnostic for prostate cancer. In addition to these tests, Diagnocure provides specialized services such as gene expression and copy number variation analysis, mutation detection, SNP genotyping, and comprehensive platform and laboratory environmental support. Established in 1994 as 9342-8530 Québec Inc. and previously known as DiagnoCure Inc., the company is headquartered in Quebec, Canada.
Τιμή μετοχής
$0.0001
Τελευταίος συγχρονισμός: 2025-06-11
Κεφαλαιοποίηση
$21.52K
Αλλαγή (1 ημέρα)
0.00%
Αλλαγή (1 έτος)
0.00%
Χώρα
CA
Εμπόριο Diagnocure, Inc. (DGCRF)

Κατηγορία

Ιστορικό τιμής μετοχής για την Diagnocure, Inc. (DGCRF)
Υψηλότερη τιμή κλεισίματος: $0.00 στις 2025-06-01

Χαμηλότερη τιμή κλεισίματος: $0.77 στις 2012-06-01
Ιστορικό τιμής μετοχής της Diagnocure, Inc. από 2012 έως 2026
Ετήσια απόδοση τιμής μετοχής
Έτος Απόδοση
2025 0.00%
2024 9,900.00%
2022 -99.50%
2021 100.00%
2020 -50.00%
2019 -77.65%
2018 -14.62%
2017 -7.14%
2016 -98.56%
2015 -20.88%
2014 -39.86%
2013 -53.79%
2012 0.00%
Τιμή μετοχής για παρόμοιες εταιρείες ή ανταγωνιστές
Εταιρεία Τιμή μετοχής Μεταβολή 1Έτ% Χώρα
$236.22 -4.39%
IE
$15.84 -13.29%
CN
$532.45 10.93%
CH
$171.67 -9.77%
CH
$2.37 -28.64%
CN